In the specific context of synchronous disease, the genetic heterogeneity of liver metastases compared to primary tumour and regional heterogeneity within metastases brings further complexity to the analysis of the influence of KRAS mutation status and sidedness [20,21]. This evidence concerns the gene KRAS and neoplasm.